FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4242158051> ?p ?o ?g. }

• W4242158051 abstract "Abstract Background： Neuromyelitis optica spectrum disorder (NMOSD) is a severe relapsing and disabling inflammatory autoimmune disease of the central nervous system. Despite the progress made in understanding the pathogenesis of the disease, the optimal first line treatment to reduce relapse rate and ameliorate neurological disability remains unclear. Mesenchymal stem cells (MSC) are known for having anti-inflammatory and regenerative properties and there are a number of studies on the use of human umbilical cord MSCs (hUC-MSCs) in NMOSD patients. Therefore, we will conduct a prospective, multicenter, randomized, placebo-controlled clinical trial to study the safety and effectiveness of hUC-MSCs in the treatment of NMOSD. Methods： The trial is planned to recruit 430 AQP4-IgG seropositive NMOSD patients. The multicenter study will be conducted in six clinical centers. The whole clinical trial consists of three consecutive stages. The first stage will be carried out in the leading center (Ren Ji Hospital) only and it will last 24 months. In the first stage the primary objective is to evaluate the safety of hUC-MSCs. Patients (n=30) will be treated with three different doses of hUC-MSC: the low dose group (n=10, 1×10 6 MSC / kg·weight), the medium dose group (n=10, 2×10 6 MSC / kg·weight) and the high dose group (n=10, 5×10 6 MSC / kg·weight). The second stage, which aims to find the optimal dosage, will last 24 months and will be carried out in six centers (one leading center and five branch centers). Patients (n=160) will be randomized into four groups by 1:1:1:1 allocation ratio: the low, medium, high dose groups and the controlled group (n=40). The third stage, which aims to evaluate the effectiveness, will lasts for 24 months and will be developed in six centers. Patients (n=320) will be 1:1 randomized into two groups: the optimal dose group (n=160) and the controlled group (n=160). HUC-MSC infusion will be given four times to the intervention groups and stem cell solution will be given four times to the control group every 3 months; besides the primary drugs will be provided to both groups. Primary endpoint is the first recurrent time and secondary endpoints are the recurrent times, EDSS scores, MRI lesion numbers, OSIS scores, Hauser walking index and SF-36 (quality of life short Form-36) scores. Exploratory endpoints will include: serum lymphocyte subsets, cytokines, complements, serum anti-AQP4 antibody titers etc. Endpoint events and side-effects will be evaluated at baseline and every 3 months for a total of 24 months follow-up. Discussion： Although hUC-MSC has shown promising treatment effect of NMOSD in preclinical study, there is still a lack of well-designed clinical trials to evaluate the safety and effectiveness of hUC-MSC among NMOSD patients. As far as we know, this trial will be the first one to systematically demonstrate the clinical safety and efficacy of hUC-MSC in treating NMOSD and might be able to determine the optimal dose of hUC-MSC for NMOSD patients. Trial registration： The study was registered with Chinese Clinical Trial Registry (CHICTR.org.cn) on Mar 2, 2016 (registration No. ChiCTR-INR-16008037), and the revised trial protocol (Protocol version 1.2.1) was released on March 16, 2020." @default.
• W4242158051 created "2022-05-12" @default.
• W4242158051 creator A5001172991 @default.
• W4242158051 creator A5006122583 @default.
• W4242158051 creator A5018532641 @default.
• W4242158051 creator A5028964836 @default.
• W4242158051 creator A5029257310 @default.
• W4242158051 creator A5029752976 @default.
• W4242158051 creator A5031321053 @default.
• W4242158051 creator A5032148207 @default.
• W4242158051 creator A5035026050 @default.
• W4242158051 creator A5042172390 @default.
• W4242158051 creator A5042921774 @default.
• W4242158051 creator A5042973046 @default.
• W4242158051 creator A5046394544 @default.
• W4242158051 creator A5048808268 @default.
• W4242158051 creator A5050030623 @default.
• W4242158051 creator A5052787170 @default.
• W4242158051 creator A5055916102 @default.
• W4242158051 creator A5059304852 @default.
• W4242158051 creator A5059372845 @default.
• W4242158051 creator A5060509734 @default.
• W4242158051 creator A5062197763 @default.
• W4242158051 creator A5062747890 @default.
• W4242158051 creator A5066846089 @default.
• W4242158051 creator A5068456388 @default.
• W4242158051 creator A5068851050 @default.
• W4242158051 creator A5069153972 @default.
• W4242158051 creator A5069291153 @default.
• W4242158051 creator A5071659144 @default.
• W4242158051 creator A5076012944 @default.
• W4242158051 creator A5078046664 @default.
• W4242158051 creator A5079953530 @default.
• W4242158051 creator A5081428042 @default.
• W4242158051 creator A5083933208 @default.
• W4242158051 creator A5087089173 @default.
• W4242158051 creator A5089812226 @default.
• W4242158051 date "2020-12-22" @default.
• W4242158051 modified "2023-10-04" @default.
• W4242158051 title "Human Umbilical Cord Mesenchymal Stem Cells to Treat Neuromyelitis Optica Spectrum Disorder (hUC-MSC-NMOSD): A Study Protocol for a Prospective, Multicenter, Randomized, Placebo-Controlled Clinical Trial" @default.
• W4242158051 doi "https://doi.org/10.21203/rs.3.rs-131661/v1" @default.
• W4242158051 hasPublicationYear "2020" @default.
• W4242158051 type Work @default.
• W4242158051 citedByCount "0" @default.
• W4242158051 crossrefType "posted-content" @default.
• W4242158051 hasAuthorship W4242158051A5001172991 @default.
• W4242158051 hasAuthorship W4242158051A5006122583 @default.
• W4242158051 hasAuthorship W4242158051A5018532641 @default.
• W4242158051 hasAuthorship W4242158051A5028964836 @default.
• W4242158051 hasAuthorship W4242158051A5029257310 @default.
• W4242158051 hasAuthorship W4242158051A5029752976 @default.
• W4242158051 hasAuthorship W4242158051A5031321053 @default.
• W4242158051 hasAuthorship W4242158051A5032148207 @default.
• W4242158051 hasAuthorship W4242158051A5035026050 @default.
• W4242158051 hasAuthorship W4242158051A5042172390 @default.
• W4242158051 hasAuthorship W4242158051A5042921774 @default.
• W4242158051 hasAuthorship W4242158051A5042973046 @default.
• W4242158051 hasAuthorship W4242158051A5046394544 @default.
• W4242158051 hasAuthorship W4242158051A5048808268 @default.
• W4242158051 hasAuthorship W4242158051A5050030623 @default.
• W4242158051 hasAuthorship W4242158051A5052787170 @default.
• W4242158051 hasAuthorship W4242158051A5055916102 @default.
• W4242158051 hasAuthorship W4242158051A5059304852 @default.
• W4242158051 hasAuthorship W4242158051A5059372845 @default.
• W4242158051 hasAuthorship W4242158051A5060509734 @default.
• W4242158051 hasAuthorship W4242158051A5062197763 @default.
• W4242158051 hasAuthorship W4242158051A5062747890 @default.
• W4242158051 hasAuthorship W4242158051A5066846089 @default.
• W4242158051 hasAuthorship W4242158051A5068456388 @default.
• W4242158051 hasAuthorship W4242158051A5068851050 @default.
• W4242158051 hasAuthorship W4242158051A5069153972 @default.
• W4242158051 hasAuthorship W4242158051A5069291153 @default.
• W4242158051 hasAuthorship W4242158051A5071659144 @default.
• W4242158051 hasAuthorship W4242158051A5076012944 @default.
• W4242158051 hasAuthorship W4242158051A5078046664 @default.
• W4242158051 hasAuthorship W4242158051A5079953530 @default.
• W4242158051 hasAuthorship W4242158051A5081428042 @default.
• W4242158051 hasAuthorship W4242158051A5083933208 @default.
• W4242158051 hasAuthorship W4242158051A5087089173 @default.
• W4242158051 hasAuthorship W4242158051A5089812226 @default.
• W4242158051 hasBestOaLocation W42421580511 @default.
• W4242158051 hasConcept C126322002 @default.
• W4242158051 hasConcept C141071460 @default.
• W4242158051 hasConcept C142724271 @default.
• W4242158051 hasConcept C168563851 @default.
• W4242158051 hasConcept C198826908 @default.
• W4242158051 hasConcept C203014093 @default.
• W4242158051 hasConcept C204787440 @default.
• W4242158051 hasConcept C27081682 @default.
• W4242158051 hasConcept C2775965419 @default.
• W4242158051 hasConcept C2776955114 @default.
• W4242158051 hasConcept C2780640218 @default.
• W4242158051 hasConcept C2781137167 @default.
• W4242158051 hasConcept C2992435398 @default.
• W4242158051 hasConcept C535046627 @default.
• W4242158051 hasConcept C71924100 @default.
• W4242158051 hasConceptScore W4242158051C126322002 @default.
• W4242158051 hasConceptScore W4242158051C141071460 @default.
• W4242158051 hasConceptScore W4242158051C142724271 @default.
• W4242158051 hasConceptScore W4242158051C168563851 @default.

• next